PERCEPTIVE ADVISORS LLC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:15 pm Sale | 2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,574,723 4.400% | -297,824 (-10.37%) | Filing |
| 2024-11-14 4:33 pm Purchase | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,872,547 5.700% | 265,868 (+10.20%) | Filing |
| 2024-02-14 4:27 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,606,679 7.200% | 0 (Unchanged) | Filing |
| 2023-12-13 3:50 pm Purchase | 2023-11-24 | 13G | Spyre Therapeutics, Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,606,679 7.200% | 2,606,679 (New Position) | Filing |